Strategic Analysis of Biomarkers in Clinical Trials


Regular Price: USD 3,950.00

Special Price USD 2,765.00

30% OFF

* Required Fields

Regular Price: USD 3,950.00

Special Price USD 2,765.00


Be the first to review this product

This strategic analysis service provides detailed analysis of the role of biomarkers in clincal trials. The service in powerpoint format (approximately 136 slides) focuses not just only on overall market revenues and competitor analysis but also on strategies for achieving success in this new and emerging market.

Table of Contents

Strategic Analysis of Biomarkers in Clinical Trials , Strategic Analysis of Biomarkers in Clinical TrialsOverviewOverviewResearch Scope & MethodologyResearch Scope & MethodologyIntroduction & BackgroundIntroduction & BackgroundMarket DynamicsMarket DynamicsMajor Challenges for Biomarkers in Clinical TrialsKey Market TrendsMarket DriversMarket RestraintsKey Market Engineering MeasurementsTotal Market Revenue ForecastRegulatory ClimateRegulatory ClimateDrug Failure in Clinical DevelopmentDecrease in FDA SubmissionsDecrease in EMEA SubmissionsCurrent FDA PolicyResearch TrendsResearch TrendsAssumptionsWorld Biomarker Research DirectionWorld Investment in Research and DevelopmentWorld Biomarker IP PortfoliosCompetitive ProfilesOther Key Industry ParticipantsMajor Challenges & Strategic ProposalsMajor Challenges and Strategic ProposalsBiomarker Misdiagnosis IssuesInvestment in BiomarkersClinical Development Productivity ImprovementBiomarker Regulatory IssuesLate Stage Clinical FailureSummary of Strategic ProposalsCorporate StrategyCorporate StrategyCorporate Strategy—Strategic AnticipationCorporate Strategy—Market Maturation ProcessCorporate Strategy—Competitive FrameworkCorporate Strategy—Potential ThreatsCorporate Strategy—Meeting the ChallengeFrost & Sullivan AwardsFrost & Sullivan AwardsFrost & Sullivan Awards DescriptionGrowth Strategy Leadership AwardTechnology Leadership AwardEntrepreneurial Company AwardMarket Leadership AwardCompetitive Strategy Leadership AwardDecision Support DatabasesDecision Support DatabasesNew Drugs Approved by the FDA (2000-2004)New Drugs Approved by the EMEA (2000-2004)Number of Biotechnology Companies—Western Europe and North America (1999-2006)Major Pharmaceutical Companies in Europe (2003)Biotechnology European Patents Filed (1996-2000)Governmental Biotechnology Investment (1999-2006)Pharmaceutical Research and Development Expenditure (1999-2006)Frost & SullivanHealthcare TeamOur Capabilities

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.